Physician profile
Anwarul Islam
NPI 1215948872
$5,904.79
in general payments reported to CMS, 2019-2025
17 companies · $962 in 2025
The $962 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $576 · 2021: $867 · 2022: $1,202 · 2023: $644 · 2024: $814 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.53 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $787.51 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $699.97 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.53 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.36 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $537.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $516.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $487.79 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $254.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.85 | 2021-2024 | |
| Amgen INC. | $158.69 | 2022 | |
| Merck Sharp & Dohme LLC | $144.78 | 2020-2022 | |
| Abbvie INC. | $41.66 | 2021-2025 | |
| Abbott Laboratories | $41.00 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.21 | 2024-2025 | Caplyta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.28 | 2023 | Austedo Xr, Austedo |
| Ultragenyx Pharmaceutical INC. | $17.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwarul Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.